Fetal parvovirus syndrome

Fetal parvovirus syndrome, also known as congenital parvovirus B19 infection, is a condition caused by maternal infection with human parvovirus B19 (the virus responsible for erythema infectiosum or 'fifth disease') during pregnancy, with subsequent transplacental transmission to the fetus. Parvovirus B19 has a strong tropism for erythroid progenitor cells, meaning it preferentially infects and destroys red blood cell precursors in the fetal bone marrow. This leads to severe fetal anemia, which can result in high-output cardiac failure, generalized edema (hydrops fetalis), and potentially fetal death. The risk of adverse fetal outcomes is highest when maternal infection occurs during the first and second trimesters of pregnancy. Key clinical features of fetal parvovirus syndrome include non-immune hydrops fetalis (characterized by fluid accumulation in at least two fetal body compartments such as ascites, pleural effusion, pericardial effusion, and skin edema), severe anemia, thrombocytopenia, hepatitis, and myocarditis. Some affected fetuses may also develop reticulocytopenia and aplastic crisis. In surviving neonates, manifestations can include congenital anemia, hepatosplenomegaly, and in rare cases, neurological complications. The overall risk of fetal loss following maternal parvovirus B19 infection is estimated at approximately 2-10%, with the risk being greatest between 9 and 20 weeks of gestation. Diagnosis is typically made through detection of parvovirus B19 DNA by PCR in amniotic fluid or fetal blood, combined with ultrasound findings of hydrops fetalis. The primary treatment for severely affected fetuses is intrauterine blood transfusion (IUT) to correct the profound anemia, which has significantly improved survival rates. Serial ultrasound monitoring, including Doppler assessment of the middle cerebral artery peak systolic velocity to detect fetal anemia, is essential for managing pregnancies complicated by parvovirus B19 infection. There is currently no vaccine available to prevent parvovirus B19 infection, and management is largely supportive. Spontaneous resolution of hydrops can occur in some cases without intervention.

Common questions about Fetal parvovirus syndrome